TNFSF10 and neoplasm: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a promising cancer therapeutic because it can selectively induce apoptosis in tumor cells in vitro, and most importantly, in vivo with little adverse effect on normal cells.1 However, a number of cancer cells are resistant to TRAIL, especially highly malignant tumors such as lung cancer.2, 3 Lung cancer, especially the non-small-cell lung carcinoma (NSCLC) constitutes a heavy threat to human life.